
Brief intro:
- Author: Andy Peng Xiang, Congyuan Liu, Hao Peng, Jiajie Yu, Hong Chen, Peng Luo, Yuanchen Ma, Wangsheng Ou, Suyuan Zhang, Cuifeng Yang, Hang Fan, Lerong Zhao, Yuchen Zhang, Xiaolu Guo, Qiong Ke, Tao Wang, Chunhua Deng, Weiqiang Li, Kai Xia
- Journal: Research Square
- Doi: https://www.doi.org/10.21203/rs.3.rs-4788949/v1
- Publication Date: 2024 Aug 8
Products/Services used in the paper
Quotation shows PackGene:Following sequencing-based verication, the constructed vector was custompackaged, puried, and titrated by Packgene Bioscience (Guangzhou, China). The
Research Field:Leydig Cells
AAV Serotype:AAVDJ
Targeted organ:testis
Animal or cell line strain:mice
Abstract
Testicular aging commonly leads to testosterone deficiency and impaired spermatogenesis, yet the underlying mechanisms remain elusive. Here, a comprehensive analysis of senescence landscapes in mice testes during aging revealed that the Leydig cells (LCs) are particularly vulnerable to aging processes. Single-cell RNA sequencing identified the expression of Hmgcs2 (3-hydroxy-3-methylglutaryl-CoA synthetase 2), the gene encoding the rate-limiting enzyme of ketogenesis, decreased significantly in LCs from aged mice. Additionally, the concentrations of ketone bodies β-hydroxybutyric acid (BHB) and acetoacetic acid (AcAc) in the young testes were substantially higher than that in serum, but significantly diminished in aged testes. Silencing of Hmgcs2 in young LCs resulted in decreased ketone body production, which in turn drived LCs senescence and accelerated testicular aging. Mechanically, BHB acted as an endogenous inhibitor of histone deacetylase 1 to upregulate the expression of Foxo3a by promoting histone acetylation, thereby mitigating LCssenescence and promoting testosterone production. Consistently, enhanced ketogenesis by genetic manipulation or oral BHB supplementation alleviated LCs senescence and ameliorated testicular aging in aged mice. These findings highlight defective ketogenesis as a pivotal factor in testicular aging, suggesting novel therapeutic avenues for addressing age-related testicular dysfunction.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
